Are you Dr. Kean?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 43 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
300 Longwood Ave
Boston, MA 02115Phone+1 617-355-6000- Is this information wrong?
Summary
- Dr. Leslie Kean, MD is a pediatric hematologist/oncologist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts, Washington, and Georgia. She is affiliated with Boston Children's Hospital and Dana-Farber Cancer Institute.
Education & Training
- Emory University School of MedicineFellowship, Pediatric Hematology/Oncology, 2003 - 2005
- Emory University School of MedicineResidency, Pediatrics, 1999 - 2003
- Emory University School of MedicineClass of 1999
Certifications & Licensure
- MA State Medical License 2018 - 2025
- WA State Medical License 2013 - 2020
- GA State Medical License 2003 - 2019
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT Start of enrollment: 2009 Nov 01
- Abatacept as GVHD Prophylaxis Phase 2 Start of enrollment: 2013 Feb 01
- Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation (The PREDICT Trial) Start of enrollment: 2017 May 01
Publications & Presentations
PubMed
- 1634 citationsSARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.Carly G. K. Ziegler, Samuel J. Allon, Sarah K. Nyquist, Ian M. Mbano, Vincent N. Miao
Cell. 2020-05-28 - 71 citationsThe Microbiome and Hematopoietic Cell Transplantation: Past, Present, and FutureTessa M. Andermann, Jonathan U. Peled, Christine M. Ho, Pavan Reddy, Marcie L. Riches
Biology of Blood and Marrow Transplantation. 2018-02-19 - 37 citationsNK cells rapidly reject allogeneic bone marrow in the spleen through a perforin- and Ly49D-dependent, but NKG2D-independent mechanism.Kelly Hamby, A. Trexler, Thomas C. Pearson, Christian P. Larsen, Mark R. Rigby
American Journal of Transplantation. 2007-08-01
Press Mentions
- Pilot Study Investigates Axicabtagene Ciloleucel in Primary and Secondary CNS LymphomaDecember 13th, 2022
- Tonix Pharmaceuticals Announces Collaboration with Boston Children’s Hospital to Study TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Graft-Versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transplantation in AnimalsDecember 5th, 2022
- From Our Labs and Clinics: 10 Research Advances in 2021December 30th, 2021
- Join now to see all
Grant Support
- Novel Biologic Therapies For BMT: Mechanistic Evaluation In Rhesus MacaquesNational Heart, Lung, And Blood Institute2010–2012
- Adoptive Cellular Therapies To Enhance Tolerance And Protective ImmunityNational Institute Of Allergy And Infectious Diseases2008–2011
- Innate Immunity And Transplantatation ToleranceNational Institute Of Allergy And Infectious Diseases2006–2009
- Innate Immunity And Transplantation ToleranceNational Institute Of Allergy And Infectious Diseases2007
Hospital Affiliations
- Dana-Farber Cancer InstituteBoston, Massachusetts
- Boston Children's HospitalBoston, Massachusetts